SCHEDULE: Todd Harris Reports 4.8% Stake in Tyra Biosciences

Todd Harris has disclosed beneficial ownership of 2,913,342 shares, representing 4.8% of Tyra Biosciences, Inc. common stock as of March 31, 2026.

Summary

• Todd Harris, an individual investor, has filed a Schedule 13G, indicating beneficial ownership of Tyra Biosciences, Inc. common stock.
• As of March 31, 2026, the reporting person beneficially owns 2,913,342 shares of common stock.
• This ownership represents 4.8% of the total outstanding shares of common stock.
• The reported shares include 1,358,631 shares held directly and 1,554,711 shares underlying exercisable stock options.
• The filing is an amendment (Amendment No. 1) to a previous filing.
• The total number of outstanding shares of common stock as of March 31, 2026, was 59,469,687.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of ownership rather than an announcement of new strategic developments or financial performance.

Positives

• Todd Harris holds a significant stake of 4.8% in Tyra Biosciences, Inc., indicating investor confidence.
• The ownership includes directly held shares and exercisable stock options, suggesting potential for increased direct ownership.
• The filing is up-to-date as of March 31, 2026, providing current ownership information.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant institutional or individual investors acquiring more than 5% of a company's stock. This filing indicates Todd Harris's substantial interest in Tyra Biosciences, Inc., a biotechnology company.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant individual shareholder's stake, which can be relevant for understanding ownership concentration.
• Company Management: The disclosure confirms Todd Harris's substantial interest, potentially influencing future strategic discussions or board representation considerations.

Key Dates

Keywords

Tyra Biosciences, Todd Harris, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Stock Options, Investment